I found a clue to increase the accuracy of breast cancer diagnosis...Up to 39%p higher accuracy than before
Jan 14, 2025
Blood tests have revealed research results that can increase the accuracy of breast cancer diagnosis.
A joint research team of professors Kim Seung-il and Kim Ji-ye of Yonsei Cancer Hospital's breast surgery department, Kim Min-woo of Yonsei University's School of Surgery, and Kim Yong of Yonsei University's Graduate School of Medicine announced on the 14th that the substance secreted by breast cancer tissue can improve the accuracy of diagnosis by supplementing the limitations of mammography, the existing breast cancer diagnosis method.
Breast imaging is mainly used in breast cancer screening, which is the number one cancer incidence in Korea. However, in the case of dense breasts with more mammary gland tissue than adipose tissue, it is difficult to diagnose because there are many areas that look white in addition to cancer.
The research team recently developed a technology to selectively separate substances secreted by breast cancer from breast cancer patients' blood based on liquid biopsies that analyze blood and track their progress.
All cells, as well as cancer cells, secrete 'extracellular endoplasmic reticulum' for intercellular signal transmission. This includes DNA and other materials such as miRNA. The research team tied up five substances corresponding to miRNA among extracellular vesicles in breast cancer patients' blood, named them EVmiR, and analyzed their expression patterns.
In order to verify the effectiveness of the development technology, a study was conducted on 120 breast cancer patients admitted to Yonsei Cancer Hospital, 46 breast-positive tumor patients, and 46 ordinary people.
As a result, the clinical sensitivity (Sensitivity) of EVmiR was 85.8%, the specificity sms 84.6%, and the breast cancer diagnosis accuracy (AUC) was 0.908. The closer the AUC is to 1, the better the performance, and if it exceeds 0.8, it is evaluated as high performance.
In the case of breast cancer patients with dense breasts, the clinical sensitivity of mammography was 56.3%, but EVmiR recorded 84.4%, and the clinical sensitivity increased to 95.3% when both methods were combined.
In addition, the research team said that EVmiR can function as a major indicator of breast cancer diagnosis as it has been confirmed that it is consistently expressed regardless of the individual physical conditions of breast cancer patients.
Professor Kim Ji-ye suggested a way to supplement the limitations of conventional mammography by developing a technology to increase the sensitivity of breast cancer diagnosis based on miRNA analysis secreted by breast cancer"We will continue to increase the accuracy of early breast cancer diagnosis through follow-up studies."
The results of the study were published in the international renowned journal 『Theranostics』 (IF 12.4).
A joint research team of professors Kim Seung-il and Kim Ji-ye of Yonsei Cancer Hospital's breast surgery department, Kim Min-woo of Yonsei University's School of Surgery, and Kim Yong of Yonsei University's Graduate School of Medicine announced on the 14th that the substance secreted by breast cancer tissue can improve the accuracy of diagnosis by supplementing the limitations of mammography, the existing breast cancer diagnosis method.
Breast imaging is mainly used in breast cancer screening, which is the number one cancer incidence in Korea. However, in the case of dense breasts with more mammary gland tissue than adipose tissue, it is difficult to diagnose because there are many areas that look white in addition to cancer.
The research team recently developed a technology to selectively separate substances secreted by breast cancer from breast cancer patients' blood based on liquid biopsies that analyze blood and track their progress.
All cells, as well as cancer cells, secrete 'extracellular endoplasmic reticulum' for intercellular signal transmission. This includes DNA and other materials such as miRNA. The research team tied up five substances corresponding to miRNA among extracellular vesicles in breast cancer patients' blood, named them EVmiR, and analyzed their expression patterns.
In order to verify the effectiveness of the development technology, a study was conducted on 120 breast cancer patients admitted to Yonsei Cancer Hospital, 46 breast-positive tumor patients, and 46 ordinary people.
As a result, the clinical sensitivity (Sensitivity) of EVmiR was 85.8%, the specificity sms 84.6%, and the breast cancer diagnosis accuracy (AUC) was 0.908. The closer the AUC is to 1, the better the performance, and if it exceeds 0.8, it is evaluated as high performance.
In the case of breast cancer patients with dense breasts, the clinical sensitivity of mammography was 56.3%, but EVmiR recorded 84.4%, and the clinical sensitivity increased to 95.3% when both methods were combined.
In addition, the research team said that EVmiR can function as a major indicator of breast cancer diagnosis as it has been confirmed that it is consistently expressed regardless of the individual physical conditions of breast cancer patients.
Professor Kim Ji-ye suggested a way to supplement the limitations of conventional mammography by developing a technology to increase the sensitivity of breast cancer diagnosis based on miRNA analysis secreted by breast cancer"We will continue to increase the accuracy of early breast cancer diagnosis through follow-up studies."
The results of the study were published in the international renowned journal 『Theranostics』 (IF 12.4).
|
This article was translated by Naver AI translator.
